Dual NRTI backbone
Abacavir with lamivudine
Brand names: Kivexa
Adult dose
Dose: 1 tablet (abacavir 600 mg / lamivudine 300 mg)
Route: Oral
Frequency: Once daily
Clinical pearls
- Pair with INSTI/PI/NNRTI as backbone
- Avoid in baseline VL >100,000 with EFV
Contraindications
- HLA-B*5701 positive
- CrCl <50 mL/min
Side effects
- Hypersensitivity
- Nausea
- Headache
Interactions
- Methadone
- Sorbitol-containing solutions reduce lamivudine AUC
Monitoring
- HIV RNA, CD4
- LFTs
Reference: BNF; BHIVA 2022; SmPC Kivexa. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways